About Catalio

Our Portfolio

Investing in the next generation of life sciences
Scroll
[Portfolio]

Companies

We focus on life sciences companies developing next-generation drugs, devices and diagnostics, data, tools, and healthcare services and work closely with each portfolio company to build and grow the business from inception to exit.
Clear filters
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Syndeio Biosciences
M&A in 2025
Private Equity
Drugs
Exited
Unrealized
US
TapestryHealth
Loan Repayment in 2025
Structured Opportunities
Diagnostics
Private
Unrealized
US
Thea AI
Private Equity
Healthcare / AI
Private
Unrealized
US
Thrive Earlier Detection
Exit in 2020
Private Equity
Co-Investments
Diagnostics
Exited
Realized
US
Visby Medical
Structured Opportunities
Co-Investments
Diagnostics
Private
Unrealized
US
Volastra Therapeutics
Private Equity
Drugs
Private
Unrealized
US
WindMIL Therapeutics
Private Equity
Drugs
Private
Unrealized
US
Winnow Therapeutics
Private Equity
Drugs
Private
Unrealized
US
Xilis, Inc.
Private Equity
Diagnostics
Private
Unrealized
US